Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Krueppel-like factor 8 (KLF8) is a member of the Sp/KLF family of transcription factors, characterized by a C-terminal DNA-binding domain with three krueppel-like zinc fingers[4][5]. KLF8 functions both as a transcriptional repressor and activator, binding to CACCC-box and GT-box promoter elements. It plays a central role in regulating cell cycle progression at the G1 phase, epithelial-to-mesenchymal transition, and oncogenic transformation[2][5]. KLF8 directly binds androgen receptor (AR) and acts as a novel co-activator, promoting AR target gene transcription, thereby enhancing prostate cancer cell proliferation and tumor growth[1]. Overexpression of KLF8 is associated with several malignancies and cancer progression, making it a potential biomarker for aggressive tumors and a putative therapeutic target in oncology[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Krueppel-like factor 8 (KLF8).